INR self-monitoring

Last updated
INR self-monitoring
Purposeself measure their INR (due to anti-coagulation therapy)

INR self-monitoring is a medical kit that is used by patients both on long-term and on lifetime anti-coagulation therapy to measure their INR (International Normalized Ratio) levels themselves at your premises without going to a clinic. People who self-monitor their INR levels use a portable INR monitor as in a clinic. It requires the patient to test a drop of blood, drawn from a finger at scheduled times, and record the INR level measured by a monitor.

Contents

Patient self-testing

INR self monitoring with one blood drop. the INR is too high and the warfarine dose must be decreased. INR self test.jpg
INR self monitoring with one blood drop. the INR is too high and the warfarine dose must be decreased.

People on anti-coagulation therapy who are self-testing provide the INR upi antem76102824@axl reading they obtain from their monitor to their healthcare professionals at an agreed time, generally by telephone. The healthcare professional decides if any change to the warfarin dose is required and lets the person know what action is needed. A PT/INR meter can be obtained by contacting an Independent Diagnostic Testing Facility (IDTF). [1] They are able to provide patients with all necessary testing equipment and bill the insurance for test results reported.[ citation needed ]

Patient self-management

People who self-manage adjust their warfarin doses themselves, following training with their healthcare professional. This means that if the INR reading obtained from their monitor is out of the normal therapeutic range, they are able to make an adjustment to their own warfarin dose by themselves.[ citation needed ]

International Normalized Ratio (INR)

International normalized ratio (INR) which is a derivative of prothrombin time is a measurement of blood coagulation in the circulatory system. Both are used to determine the clotting rate of blood, which can be affected by anticoagulant usage, liver damage and Vitamin K levels. The preferred range of INR levels for a patient on anticoagulation therapy is usually between 2 and 3, but it tends to vary depending on the patient's requirements. [2]

The advantages of self-monitoring

Patients who self-monitor tend to choose this route for the greater control they feel it gives them over their lives and their condition. This helps to reduce the number of visits being made to their anticoagulation clinic for routine appointments to measure their INR levels. This is a lengthy process in comparison to self-testing and management. Results of clinical studies, which have been recognized by the National Patients Safety Authority (NPSA), show that people who self-monitor keep more frequently within their therapeutic range and have fewer complications including clots and bleeding, compared with people who have their INR levels tested only at their anticoagulation clinic.[ citation needed ]

UK NHS on self-monitoring

Patient self-care is a key initiative in the NHS Plan for a patient-centered health service and an important component in supporting people with long-term conditions. [3] It is seen to provide:

Who self-monitoring is suitable for

Self-monitoring may be a suitable option for a variety of people who are on long term anticoagulation therapy and want the convenience of being able to monitor their own INR levels at a time and place of their own choosing (e.g. if travelling abroad either with work or on vacation). They do have continuous support from their healthcare professionals and there are no upper age limits for self-monitoring and parents can take charge for their children. Self-monitoring is ideal if:[ citation needed ]

Clinical trials

In the past 5 years, there have been a number of clinical trials to highlight the advantages of self-monitoring, whether self-testing or self-managing. It also gives an indication of what improvements the self-testing and self-management can do to INR levels.[ citation needed ]

Clinical reports about INR self-monitoring

"Quality of life changed in a positive way. Independence and better organisation of vacation and spare time were most frequently mentioned advantages."

Extract from a study into the impact of self-monitoring on the quality of life of patients under anticoagulation therapy. [6]

"Patient self-testing . . . is an effective method of monitoring oral anticoagulation therapy, providing outcomes at least as good as, and possibly better than, those achieved with an anti-coagulation clinic."

From international consensus guidelines prepared by the International Self-Monitoring Association for Oral Anti-coagulation. [7]

"Self-monitoring can improve the quality of oral anti-coagulation therapy, with patients more frequently in the therapeutic range, while improving benefits and decreasing harm."

From the conclusions of a review of studies of self-monitoring in oral anti-coagulation therapy. [8] [9]

The results of the study Effect of Home Testing of International Normalized Ratio on Clinical Events (2010), comparing whether weekly home-testing of the INR-level offers any advantage over monthly testing in a clinic, reduces the risk of a major hemorrhage event (i.e. stroke, major bleeding, or death), indicated that the time to the first primary-event (stroke, major bleeding, or death) was not significantly longer in the self-testing group of patients than in the clinic-testing group of patients (hazard ratio, 0.88; 95% confidence interval, 0.75 to 1.04; p=0.14). The study was a prospective, randomized, non-blinded trial for which the patients were randomized into two groups, (i) weekly INR self-testing and (ii) monthly INR clinic-testing, using a stratified method of adaptive-allocation that was determined according to the duration of anti-coagulation and the indication for Warfarin. Although the study was non-blinded, blinding is less critical because the objective outcomes of the study: stroke, major bleeding episode, and death. [10]

Monitors

Patients who are self-monitoring have to use a monitor in order to measure their INR level. There are a range of INR testing monitors on the market, such as the CoaguChek XS, [11] [12] MicroINR., [13] INRatio2, [14] and QLabs [15]

See also

Related Research Articles

<span class="mw-page-title-main">Anticoagulant</span> Class of drugs

An anticoagulant, commonly known as a blood thinner, is a chemical substance that prevents or reduces the coagulation of blood, prolonging the clotting time. Some occur naturally in blood-eating animals, such as leeches and mosquitoes, which help keep the bite area unclotted long enough for the animal to obtain blood.

Liver function tests, also referred to as a hepatic panel, are groups of blood tests that provide information about the state of a patient's liver. These tests include prothrombin time (PT/INR), activated partial thromboplastin time (aPTT), albumin, bilirubin, and others. The liver transaminases aspartate transaminase and alanine transaminase are useful biomarkers of liver injury in a patient with some degree of intact liver function.

<span class="mw-page-title-main">Warfarin</span> Anticoagulant medication

Warfarin, sold under the brand name Coumadin among others, is an anticoagulant medication. While the drug is described as a "blood thinner", it does not reduce viscosity but rather prevents blood clots (thrombus) from forming (coagulating). Accordingly, it is commonly used to prevent deep vein thrombosis and pulmonary embolism, and to protect against stroke in people who have atrial fibrillation, valvular heart disease, or artificial heart valves. Warfarin may sometimes be prescribed following ST-segment elevation myocardial infarctions (STEMI) and orthopedic surgery. It is usually taken by mouth, but may also be administered intravenously. It is a vitamin K antagonist.

Low-molecular-weight heparin (LMWH) is a class of anticoagulant medications. They are used in the prevention of blood clots and, in the treatment of venous thromboembolism, and the treatment of myocardial infarction.

<span class="mw-page-title-main">Prothrombin time</span> Blood test that evaluates clotting

The prothrombin time (PT) – along with its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) – is an assay for evaluating the extrinsic pathway and common pathway of coagulation. This blood test is also called protime INR and PT/INR. They are used to determine the clotting tendency of blood, in such things as the measure of warfarin dosage, liver damage, and vitamin K status. PT measures the following coagulation factors: I (fibrinogen), II (prothrombin), V (proaccelerin), VII (proconvertin), and X.

<span class="mw-page-title-main">Bleeding diathesis</span> High tendency to bleed due to a blood clotting disorder

In medicine (hematology), bleeding diathesis is an unusual susceptibility to bleed (hemorrhage) mostly due to hypocoagulability, in turn caused by a coagulopathy. Therefore, this may result in the reduction of platelets being produced and leads to excessive bleeding. Several types of coagulopathy are distinguished, ranging from mild to lethal. Coagulopathy can be caused by thinning of the skin, such that the skin is weakened and is bruised easily and frequently without any trauma or injury to the body. Also, coagulopathy can be contributed by impaired wound healing or impaired clot formation.

<span class="mw-page-title-main">Ximelagatran</span> Anticoagulant

Ximelagatran is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would withdraw pending applications for marketing approval after reports of hepatotoxicity during trials, and discontinue its distribution in countries where the drug had been approved.

<span class="mw-page-title-main">Argatroban</span> Pharmaceutical drug

Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor. In 2000, argatroban was licensed by the US Food and Drug Administration (FDA) for prophylaxis or treatment of thrombosis in people with heparin-induced thrombocytopenia (HIT). In 2002, it was approved for use during percutaneous coronary interventions in people who have HIT or are at risk for developing it. In 2012, it was approved by the UK Medicines and Healthcare products Regulatory Agency for anticoagulation in people with heparin-induced thrombocytopenia Type II (HIT) who require parenteral antithrombotic therapy.

<span class="mw-page-title-main">Rivaroxaban</span> Anticoagulant drug

Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication used to treat and prevent blood clots. Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. It is taken by mouth.

<span class="mw-page-title-main">Warfarin necrosis</span> Medical condition

Warfarin-induced skin necrosis is a condition in which skin and subcutaneous tissue necrosis occurs due to acquired protein C deficiency following treatment with anti-vitamin K anticoagulants.

<span class="mw-page-title-main">Phenprocoumon</span> Drug

Phenprocoumon is a long-acting anticoagulant to be taken by mouth, and a coumarin derivative. It acts as a vitamin K antagonist and inhibits blood clotting (coagulation) by blocking synthesis of coagulation factors II, VII, IX and X. It is used for the prophylaxis and treatment of thromboembolic disorders such as heart attacks and pulmonary (lung) embolism. The most common adverse effect is bleeding. The drug interacts with a large number of other medications, including aspirin and St John's Wort. It is the standard coumarin used in Germany, Austria, and other European countries.

<span class="mw-page-title-main">Dabigatran</span> Anticoagulant medication

Dabigatran, sold under the brand name Pradaxa among others, is an anticoagulant used to treat and prevent blood clots and to prevent stroke in people with atrial fibrillation. Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests. In a meta analysis of 7 different studies, there was no benefit of dabigatran over warfarin in preventing ischemic stroke; however, dabigatran were associated with a lower hazard for intracranial bleeding compared with warfarin, but also had a higher risk of gastrointestinal bleeding relative to warfarin. It is taken by mouth.

Prothrombin complex concentrate (PCC), also known as factor IX complex, sold under the brand name Kcentra among others, is a combination medication made up of blood clotting factors II, IX, and X(3-factor PCC) or, when also containing factor VII as does Kcentra, 4-factor PCC. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available. It may also be used for reversal of warfarin therapy. It is given by slow injection into a vein. Another product, activated prothrombin complex concentrate or FEIBA, may be used for acquired hemophilia.

Hypercoagulability in pregnancy is the propensity of pregnant women to develop thrombosis. Pregnancy itself is a factor of hypercoagulability, as a physiologically adaptive mechanism to prevent post partum bleeding. However, when combined with an additional underlying hypercoagulable states, the risk of thrombosis or embolism may become substantial.

The CHADS2 score and its updated version, the CHA2DS2-VASc score, are clinical prediction rules for estimating the risk of stroke in people with non-rheumatic atrial fibrillation (AF), a common and serious heart arrhythmia associated with thromboembolic stroke. Such a score is used to determine whether or not treatment is required with anticoagulation therapy or antiplatelet therapy, since AF can cause stasis of blood in the upper heart chambers, leading to the formation of a mural thrombus that can dislodge into the blood flow, reach the brain, cut off supply to the brain, and cause a stroke.

Clotting time is a general term for the time required for a sample of blood to form a clot, or, in medical terms, coagulate. The term "clotting time" is often used when referring to tests such as the prothrombin time (PT), activated partial thromboplastin time, activated clotting time (ACT), thrombin time (TT), or Reptilase time. These tests are coagulation studies performed to assess the natural clotting ability of a sample of blood. In a clinical setting, healthcare providers will order one of these tests to evaluate a patient's blood for any abnormalities in the time it takes for their blood to clot. Each test involves adding a specific substance to the blood and measuring the time until the blood forms fibrin which is one of the first signs of clotted blood. Each test points to a different component of the clotting sequence which is made up of coagulation factors that help form clots. Abnormal results could be due to a number of reasons including, but, not limited to, deficiency in clotting factors, dysfunction of clotting factors, blood-thinning medications, medication side-effects, platelet deficiency, inherited bleeding or clotting disorders, liver disease, or advanced illness resulting in a medical emergency known as disseminated intravascular coagulation (DIC).

Direct factor Xa inhibitors (xabans) are anticoagulants, used to both treat and prevent blood clots in veins, and prevent stroke and embolism in people with atrial fibrillation (AF).

The SAMe-TT2R2 score is a clinical prediction rule to predict the quality of vitamin K antagonist anticoagulation therapy as measured by time in therapeutic INR range (TTR) (VKA e.g. warfarin). It has been suggested that it can aid in the medical decision making between VKAs and new oral anticoagulant/non-VKA oral anticoagulant (NOAC e.g. dabigatran, rivaroxaban, apixaban or edoxaban) in patients with atrial fibrillation (AF). This score can be used with patients with ≥1 additional stroke risk factors using the CHA2DS2-VASc score, where oral anticoagulation is recommended or should be considered.

Pump thrombosis (PT) is considered a specific case of a major device malfunction, and is classified as either suspected or confirmed pump thrombus. Typically, the device is an implanted blood pump such as a left ventricular assist device. The malfunction is a blockage in the flow of blood anywhere along a vessel and it is mainly due to the bio-incompatible presence of a fairly complex mechanical apparatus. Pump thrombus is dreaded complication of CF LVAD technology that can require repeat surgery to replace the pump or lead to death.

<span class="mw-page-title-main">Tecarfarin</span> Chemical compound

Tecarfarin is a vitamin K antagonist under development for use as an anticoagulant. A Phase II/III clinical trial in 607 people, comparing it to the established vitamin K antagonist warfarin, found no difference in quality of anticoagulation or side effects between the two drugs in the overall population. Among patients taking CYP2C9 interacting drugs however, the tecarfarin patients’ TTR was 72.2% (n=92) vs 69.9% (n=87) for warfarin patients (pint=0.16); among patients who had both a CYP2C9 variant allele and taking a CYP2C9 interacting drug, TTR was 76.5% and 69.5% for the tecarfarin (n=24) and warfarin (n=31) groups, respectively (pint=0.24). This study included in 84 (14%) patients with a mechanical heart valve as an indication for anticoagulation therapy. No thrombotic or embolic events were observed in the tecarfarin treated subjects. In contrast to warfarin, tecarfarin is not affected by the cytochrome P450 inhibiting drug fluconazole, indicating a lower potential for interactions with other drugs.

References

  1. ↑ "PT/INR Home Testing Service | How our Service Works". Archived from the original on 2014-03-03. Retrieved 2014-02-27.
  2. ↑ "International Normalized Ratio - Health Encyclopedia - University of Rochester Medical Center". www.urmc.rochester.edu. Retrieved 2022-10-27.
  3. ↑ "Self care - A real choice: Self care support - A practical option : Department of Health - Publications and statistics". www.dh.gov.uk. Archived from the original on 2007-03-23.
  4. ↑ Kulinna, W., Ney, D., Wenzel, T., Heene, D., & Harenberg, J. (1999). The Effect of Self-Monitoring the INR on Quality of Anticoagulation and Quality of Life. Seminars in Thrombosis and Hemostasis, 25(01), 123–126. doi:10.1055/s-2007-996435
  5. ↑ Gadisseur APA et al. Ann Intern Med 2004:2:584-91
  6. ↑ Kulinna, W., Ney, D., Wenzel, T., Heene, D., & Harenberg, J. (1999). The Effect of Self-Monitoring the INR on Quality of Anticoagulation and Quality of Life. Seminars in Thrombosis and Hemostasis, 25(01), 123–126. doi:10.1055/s-2007-996435
  7. ↑ Ansell J. et al. International Journal of Cardiology 2005:99:37-45
  8. ↑ Heneghan, Carl, et al. "Self-monitoring of oral anticoagulation: a systematic review and meta-analysis." The Lancet 367.9508 (2006): 404-411.
  9. ↑ http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD003839/frame.html
  10. ↑ Matchar, D.B. (2010)"Effect of home testing of international normalized ratio on clinical events."
  11. ↑ "CoaguChek XS PT Test Strips". Archived from the original on 2017-02-11. Retrieved 2017-02-10.
  12. ↑ "Home | Discover INR self-testing with CoaguChek from Roche".
  13. ↑ "ILine microsystems". Archived from the original on 2019-04-17. Retrieved 2011-11-06.
  14. ↑ "Alere INRatio PT/INR Monitoring System - Home". www.alereinratio.pl. Archived from the original on 2011-02-21.
  15. ↑ "QLabs Q1 model 2019 PL – RedMed".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.